<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: Endoscopic eradication therapy is frequently used to treat <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This review addresses some of the recent developments in the field of endoscopic eradication therapy for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RECENT FINDINGS: Data on the effectiveness of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> ablation programs have been published recently, with excellent results for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> eradication </plain></SENT>
<SENT sid="3" pm="."><plain>Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> seen in some cases, particularly at the gastroesophageal junction </plain></SENT>
<SENT sid="4" pm="."><plain>Risk factors for failed ablation include longer <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> segments and persistent <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, and a simplified RFA algorithm </plain></SENT>
<SENT sid="6" pm="."><plain>New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, but not for nondysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>A systematic review has shown that <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> are rare (âˆ¼2%) with intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, supporting the use of endoscopic eradication for that lesion </plain></SENT>
<SENT sid="8" pm="."><plain>SUMMARY: Research and clinical experience with the endoscopic therapies for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> continue to grow </plain></SENT>
<SENT sid="9" pm="."><plain>Proper patient selection and technique are critical for ensuring a good outcome </plain></SENT>
<SENT sid="10" pm="."><plain>Endoscopic surveillance after any of the ablative therapies still appears to be necessary </plain></SENT>
</text></document>